Ozempic among drugs selected for Medicare price negotiations as Biden exits
The Biden administration announced on Friday the selection of the next 15 prescription drugs that will undergo price negotiations between manufacturers and Medicare, three days before President-elect Donald Trump is set to take office and take over the program.
Ozempic, Wegovy and other new drugs are selected for Medicare’s price negotiations
Biden administration says popular weight loss drugs have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers
Medicare to Negotiate Lower Prices for Weight-Loss Drugs
The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.
Medicare announces 15 new drugs chosen for price negotiations, including popular weight loss drug Ozempic
Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price negotiations, federal health officials announced Friday. At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
Ozempic, Ibrance among next drugs picked by Medicare for price talks
Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health policy acts.
Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.
Medicare targets 15 more drugs for price negotiations — including Ozempic
On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.
Novo's Ozempic, Wegovy picked for US Medicare price negotiations
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday, part of a law pharmaceutical companies have pledged to revisit with the Trump administration.
Investor's Business Daily on MSN11h
Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks
Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with a lot of ...
7 Shakeups That Could Happen for Retirees on Day 1 of Trump’s Presidency
Retirees could feel the economic impact of President-elect Donald Trump prepares to reclaim office in Washington, DC. In his ...
Gallup: Many Americans skeptical about Trump helping lower cost of healthcare
President-elect Donald Trump faces deep skepticism that his administration's policies will make health care more affordable, ...
Medicare and telehealth: more restrictive rules could hit patients in 2025
Instead, people on Medicare won’t get the two years of continued coverage for telehealth appointments and five years’ for ...
WHDH15h
Ozempic and Wegovy selected for next round of Medicare drug price negotiations
Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...
Employers outline health priorities under Trump
Groups representing employers that offer health insurance are gearing up to defend and try to bolster the largest source of ...
Social Security Update: Economist Warns Trump Plan May Speed Up Insolvency
Francois Melese warned in a recent op-ed of the damaging effects of Trump's plan to end Social Security taxes.